The Center for Continuing Medical Education (CCME)
  1. Home
  2. Conferences
  3. Diabetes Dialogue: Controversies of Cardiovascular Benefits of SGLT2 Inhibitors.

Diabetes Dialogue: Controversies of Cardiovascular Benefits of SGLT2 Inhibitors.

Thursday, September 8, 2016

This conference has already taken place.

The Fawcett Center - Columbus, OH
1 Day Conference September 8th, 2016
1.50 AMA PRA Category 1 Credit™ Hours

Description

This Dialogue, certified for 1.5 AMA PRA Category 1 credit(s)TM, is dinner meeting.  Dinner is served about 6:45.  The presentation will begin at 7:00 and last until 8:00- 8:15.  That will be followed by a 15 minutes question and answer session moderated by Dr. Kwame Osei.  This interactive  format will help the learners address professional gaps, allowing healthcare professionals in the community time to get questions pertinent to their clinical practice answered.  
Register

For pricing information, see pricing tab below.

Dates and Times

Start: 9/8/2016 12:00 AM
End: 9/8/2016 12:00 AM

Objectives

At the end of this educational activity, learners should be able to:

1.  Discuss the SGLT2 inhibitors on the cardiovascular system in diabetes

2.  Discuss the effects of SGLT2 inhibitors  on CVD outcomes

Pricing

Tier Price
All $15.00

Speakers

  • Dr. David Bradley, MD
    • Diabetes Dialogue: Controversies of Cardiovascular Benefits of SGLT2 Inhibitors.

Location

The Fawcett Center
2400 Olentangy River Road
Columbus, OH 43201

Accreditation Statement

The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Ohio State University designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.